Acuvax cashes in RESprotect

By Kate McDonald
Wednesday, 15 April, 2009

Vaccine developer Acuvax, formerly known as Avantogen, has sold its 10 per cent stake in a German company to raise cash.

The German company, RESprotect, is the original inventor and developer of pancreatic cancer drug RP101, the North American rights to which Acuvax owns 43 per cent.

The drug is being developed in North America by Acuvax’s partner SciClone Pharmaceuticals, which owns the majority rights. RESprotect retains the rights in the rest of the world.

The Brisbane company, which is also affiliated with dengue fever developer Hawaii Biotech, said the sale was worth $750,000 and would bring in $410,000 in cash.

Related News

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd